Literature DB >> 4264560

High-dose daunorubicin therapy for acute nonlymphocytic leukemia: correlation of response and toxicity with pharmacokinetics and intracellular daunorubicin reductase activity.

W Greene, D Huffman, P H Wiernik, S Schimpff, R Benjamin, N Bachur.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1972        PMID： 4264560     DOI： 10.1002/1097-0142(197212)30:6<1419::aid-cncr2820300602>3.0.co;2-i

Source DB:  PubMed          Journal:  Cancer        ISSN： 0008-543X            Impact factor:   6.860


× No keyword cloud information.
  10 in total

1.  Metabolism of epirubicin to glucuronides: relationship to the pharmacodynamics of the drug.

Authors:  J Robert; M David; C Granger
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

2.  A pharmacokinetic study of adriamycin and 4'epi-adriamycin after simultaneous intra-arterial liver administration.

Authors:  S Eksborg; M Andersson; L Domellöf; U Lönroth
Journal:  Med Oncol Tumor Pharmacother       Date:  1986

3.  Combination chemotherapy.

Authors:  E Frei
Journal:  Proc R Soc Med       Date:  1974-06

Review 4.  Use of pharmacokinetic-pharmacodynamic relationships in the development of new anthracyclines.

Authors:  J Robert
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

5.  Phase I study of liposomal daunorubicin in patients with acute leukemia.

Authors:  J Cortes; S O'Brien; E Estey; F Giles; M Keating; H Kantarjian
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

6.  Dose-dependent skin ulcers in mice treated with DNA binding antitumor antibiotics.

Authors:  M J Soble; R T Dorr; P Plezia; S Breckenridge
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

7.  Contribution of drug transport and reductases to daunorubicin resistance in human myelocytic cells.

Authors:  G Vasanthakumar; N K Ahmed
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

8.  Kinetics and sensitivity of daunorubicin in patients with acute leukemia.

Authors:  M W DeGregorio; W M Holleran; B A Macher; C A Linker; J R Wilbur
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

9.  Uptake and metabolism of daunorubicin by human leukemia cells.

Authors:  M W DeGregorio; C J Carrera; J C Klock; J R Wilbur
Journal:  Cancer Chemother Pharmacol       Date:  1982-12       Impact factor: 3.333

10.  Population pharmacokinetics of Daunorubicin in adult patients with acute myeloid leukemia.

Authors:  Savitha Varatharajan; John C Panetta; Ajay Abraham; Sreeja Karathedath; Ezhilpavai Mohanan; Kavitha M Lakshmi; Nancy Arthur; Vivi M Srivastava; Sandeep Nemani; Biju George; Alok Srivastava; Vikram Mathews; Poonkuzhali Balasubramanian
Journal:  Cancer Chemother Pharmacol       Date:  2016-10-13       Impact factor: 3.333
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.